Cancer NetworkOriginal article
<![CDATA[BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer]]>
Phase 3negativeBNT113PembrolizumabNegative
AI Analysis
Summary
BNT113 plus pembrolizumab failed to meet the primary progression-free survival endpoint in the phase 2/3 AHEAD-MERIT trial for HPV16+ head and neck cancer. The trial will continue to assess overall survival outcomes.
Clinical Trial Data
Phase
2/3
Primary Endpoint
Not Met
Outcome Details
Missed primary PFS (progression-free survival) endpoint
Importance:7/10
Sentiment:
-0.80
oncologyhead and neck cancerimmunotherapyclinical trialendpoint missHPV16
Read the original article
Published by Cancer Network on October 13, 2026 2:00 PM